SEC Form 4 · accession 0001562180-18-003544
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Norman David Eansor
Officer — SVP - Novus Biologicals
Period of report
Aug 7, 2018
Accepted (ET)
Aug 9, 2018 · 6:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2018 | M | 1,199 | $0.00 | A | 3,465 | D | |
| Common Stock | Aug 7, 2018 | F | 348 | $180.14 | D | 3,117 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 7, 2018 | M | 1,199 | D | — | — | Common Stock | 1,199 | 301 | D |
| Restricted Stock UnitsF1,F2 | — | Aug 7, 2018 | D | 301 | D | — | — | Common Stock | 301 | 0 | D |
| Stock Options (Right to buy)F3 | $108.49 | Aug 7, 2018 | D | 1,881 | D | — | Aug 7, 2022 | Common Stock | 1,881 | 7,494 | D |
| Restricted Stock UnitsF1,F4 | — | Aug 8, 2018 | A | 2,537 | A | — | — | Common Stock | 2,537 | 2,537 | D |
| Stock Options (Right to buy)F5 | $177.32 | Aug 8, 2018 | A | 18,066 | A | — | Aug 8, 2025 | Common Stock | 18,066 | 18,066 | D |
| Stock Options (Right to buy)F4 | $177.32 | Aug 8, 2018 | A | 13,550 | A | — | Aug 8, 2025 | Common Stock | 13,550 | 13,550 | D |
| Restricted Stock UnitsF1,F6 | — | holding | — | — | — | — | — | Common Stock | 2,287 | 2,287 | D |
| Restricted Stock UnitsF1,F7 | — | holding | — | — | — | — | — | Common Stock | 2,174 | 2,174 | D |
| Stock Option (Right to Buy)F8 | $108.49 | holding | — | — | — | — | Aug 7, 2022 | Common Stock | 12,500 | 12,500 | D |
| Stock Option (Right to Buy)F9 | $94.35 | holding | — | — | — | — | Aug 12, 2021 | Common Stock | 15,000 | 15,000 | D |
| Stock Options (Right to buy)F7 | $125.05 | holding | — | — | — | — | Aug 9, 2024 | Common Stock | 11,982 | 11,982 | D |
| Stock Options (Right to buy)F10 | $125.05 | holding | — | — | — | — | Aug 9, 2024 | Common Stock | 15,976 | 15,976 | D |
| Stock Options (Right to buy)F11 | $106.59 | holding | — | — | — | — | Aug 18, 2023 | Common Stock | 18,819 | 18,819 | D |
| Stock Options (Right to buy)F6 | $106.59 | holding | — | — | — | — | Aug 18, 2023 | Common Stock | 14,114 | 14,114 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F10Vest 3,994 shares on each 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021
- F11Vests 4,705 shares on 8/18/17, 8/18/18, and 8/18/19 and 4,704 shares on 8/18/20.
- F2On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited.
- F3On 8/7/2018, the Board of Directors authorized discretionary vesting for 7,494 performance options. The remainder of the performance options were forfeited.
- F4Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F5Vests 4,517 shares each on 8/8/2019, 8/8/2020 and 4,516 shares each on 8/8/2021, 8/8/2022.
- F6Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F7Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F83,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- F93,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.